Stories from people navigating mismatch repair deficiency — diagnosis, treatment, caregiving, and the ordinary days in between.
6 stories
Oncology
The indication covers adults with stage II or III locally advanced rectal cancer that is MSI-H or dMMR, as established with an FDA-authorized test.
Rayan Salih · November 9, 2026 · 6 min
Oncology
Accelerated approval adds dostarlimab as an initial option for selected patients with untreated stage II or III MSI-H or dMMR rectal cancer, making organ preservation an early multidisciplinary decision.
Rayan Salih · 6 min read
Oncology
The FDA approval applies to adults with untreated stage II or III locally advanced rectal cancer whose tumors are MSI-H or dMMR. Testing must occur before the initial treatment strategy is fixed.
Rayan Salih · 6 min read
Oncology
The FDA approved atezolizumab plus fluoropyrimidine- and oxaliplatin-based chemotherapy after surgery for stage III mismatch-repair-deficient colon cancer.
Rayan Salih · 7 min read
Oncology
The FDA approved adjuvant atezolizumab plus chemotherapy for adults and patients aged 12 years or older with resected stage III mismatch-repair-deficient colon cancer.
Rayan Salih · 6 min read
Oncology
The FDA approved adjuvant atezolizumab plus chemotherapy for adults and children aged 12 years and older with resected stage III mismatch-repair-deficient colon cancer.
Rayan Salih · 7 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.